Atlas Trials

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Clinical trial NCT04889768 · UNKNOWN

Trial details

NCT number
NCT04889768
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
Start date
2021-07-31
Primary completion
2023-07-31
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.